A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With beta-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral beta-A(T87Q)-Globin Vector (LentiGlobin BB305 Drug Product)

Trial Profile

A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With beta-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral beta-A(T87Q)-Globin Vector (LentiGlobin BB305 Drug Product)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 May 2017

At a glance

  • Drugs BB305 beta-globin gene therapy bluebird bio (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NorthStar
  • Sponsors bluebird bio
  • Most Recent Events

    • 05 Dec 2016 Interim results published in the bluebird bio Media Release
    • 03 Nov 2016 Results published in a bluebird bio media release.
    • 03 Nov 2016 Data from this trial will be presented at the American Society of Hematology (ASH) Annual Meeting, according to a bluebird bio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top